Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Seattle Genetics, Inc. $575 Million Equity Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC…
Atara Biotherapeutics, Inc. Common Stock and Pre-Funded Warrants Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $150…
Forty Seven, Inc. $86 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an $86…
Davis Polk Advises the Goldman Sachs Merchant Banking Division on Its Investment in MedVet
Davis Polk is advising the Goldman Sachs Merchant Banking Division in connection with its investment in MedVet.
Founded in…
RoundTable Healthcare Partners formation of its Equity Fund V
Davis Polk advised RoundTable Healthcare Partners in connection with the formation of, and the sale of limited partner…
Hutchison China Meditech Limited $282 Million Secondary Offering
Davis Polk advised the underwriter in connection with a secondary offering of 12,000,000 American Depositary Shares of…
Medtronic Global Holdings S.C.A. €5 Billion Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €5…
Davis Polk Advises McKesson on Change Healthcare’s Initial Public Offering and Concurrent Equity Units Offering
Davis Polk advised McKesson Corporation on Change Healthcare Inc.’s SEC-registered initial public offering of 49,285,713…
Gamida Cell Ltd. $35 Million Follow-On Offering
Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares…
The Medicines Company $172.5 Million Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by The Medicines Company of 5,227…